Fig. 7: Efficacy of IV BCG in orthotopic lung cancer models. | Nature Communications

Fig. 7: Efficacy of IV BCG in orthotopic lung cancer models.

From: Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung

Fig. 7

a Schematic diagram showing treatment strategy. b Survival curves of mice bearing orthotopic LLC tumors and treated with IV PBS (n = 6) or BCG (n = 6) at day 7, from one experiment representative of two independent experiments. c Representative H&E images of tumor-bearing lungs of PBS (n = 5) or BCG (n = 6) -treated mice (at day 7) at day 20 after inoculation of LLC tumor cells, and quantification of the tumor area, number of tumor nodules and average area per tumor nodule in lung cross-sections, from one experiment. Scale bars correspond to 1 mm in length. d Survival curve of mice bearing orthotopic LLC tumors and treated with IV PBS (n = 9) or BCG (n = 6) at day 14, from one experiment. e Survival curve of mice bearing orthotopic TC-1 tumors and treated with IV PBS (n = 6) or BCG (n = 8) at day 7, from one experiment. f Survival curves of IFNγ−/−, Perf−/− or Batf3−/− mice bearing orthotopic LLC tumors and treated with IV PBS or BCG at day 7 (n = 8 mice/group, pooled from two independent experiments). g Survival curve of mice bearing orthotopic LLC-B2m−/− tumors and treated with IV PBS (n = 6) or BCG (n = 6) at day 7, from one experiment. P values were calculated using two-tailed unpaired Student’s t test at a 95 % CI (c) or log-rank (Mantel-Cox) test (b, d–g). Data depicted as mean ± SEM (c). PBS phosphate-buffered saline, IV intravenous, NK natural killer, Perf perforin, B2m Beta-2 microglobulin.

Back to article page